Growing up with midazolam in the neonatal and pediatric intensive care

Current Drug Metabolism

Volumn 13, Issue 6, 2012, Pages 760-766

  Swart, Eleonora L ^a   Slort, Pauline R ^a   Plötz, Frans B ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Tergooiziekenhuizen ^*  (Netherlands)

Author keywords

Midazolam; Neonatal intensive care unit; Pediatric intensive care unit; Pharmacodynamics; Pharmacokinetics

Indexed keywords

MIDAZOLAM;

ARTICLE; CHILD; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG RECEPTOR BINDING; HUMAN; KIDNEY FUNCTION; LIVER METABOLISM; NEWBORN INTENSIVE CARE; PHARMACODYNAMICS; SEDATION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

ANIMALS; CHILD, PRESCHOOL; HUMANS; HYPNOTICS AND SEDATIVES; INTENSIVE CARE UNITS, NEONATAL; INTENSIVE CARE UNITS, PEDIATRIC; INTENSIVE CARE, NEONATAL; MIDAZOLAM;

EID: 84863678855     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/138920012800840347     Document Type: Article

References (64)

1. Ostermann, M. E.; Keenan, S. P.; Seiferling, R. A.; Sibbald, W. J. Sedation in the intensive care unit: a systematic review. JAMA, 2000, 283, 1451-9
2. Fraser, G. L.; Prato, B. S.; Riker, R. R.; Berthiaume, D.; Wilkins, M. L. Frequency, severity, and treatment of agitation in young versus elderly patients in the ICU. Pharmacotherapy, 2000, 20, 75-82
3. Kollef, M. H.; Levy, N. T.; Ahrens, T. S.; Schaiff, R.; Prentice, D.; Sherman, G. The use of continuous i.v. sedation is associated with prolongation of mechanical ventilation. Chest, 1998, 114, 541-8.
4. Playfor, S.; Jenkins, I.; Boyles, C.; Choonara, I.; Davies, G.; Haywood, T.; Hinson, G.; Mayor, A.; Morton, N.; Ralph, T.; Wolf, A. United Kingdom Paediatric Intensive Care Society Sedation and Analgesia and Neuromuscular Blockade Working Group. Consensus guidelines on sedation and analgesia in critically ill children. Intensive Care Med., 2006, 32, 1125-36
5. Hartman, M. E.; McCrory, D. C.; Schulman, S. R. Efficacy of sedation regimens to facilitate mechanical ventilation in the pediat-ric intensive care unit: a systemic review. Pediatr. Crit. Care Med., 2009, 10, 246-55.
6. Young, C.; Knudsen, N.; Hilton, A.; Reves, J. G. Sedation in the intensive care unit. Crit. Care Med., 2000, 28, 854-66
7. de Gast Bakker, D. A.; van der Werff, S. D.; Sibarani-Ponsen, R.; Swart, E. L.; Plötz, F. B. Age is of influence on midazolam requirements in a paediatric intensive care unit. Acta Paediatr., 2007, 96, 414-7
8. Scolnik, D.; Koren, G. Principles of pharmacokinetics and phar-macodynamics. In: Gluckman PD, Heymann MA (eds) Pediatrics and perinatology, the scientific basis, 2nd ed. Arnold, London, 1996;pp. 963-7
9. Jacqz-Aigrain, E.; Wood, C.; Robieux, I. Pharmacokinetics of midazolam in critically ill neonates. Eur. J. Clin. Pharmacol., 1990, 39, 191-2
10. Jacqz-Aigrain, E.; Daoud, P.; Burtin, P.; Maherzi, S.; Beaufils, F. Pharmacokinetics of midazolam during continuous infusion in critically ill neonates. Eur. J. Clin. Pharmacol., 1992, 42, 329-32
11. Burtin, P.; Jacqz-Aigrain, E.; Girard, P.; Lenclen, R.; Magny, J. F.; Betremieux, P.; Tehiry, C.; Desplanques, L.; Mussat, P. Population pharmacokinetics of midazolam in neonates. Clin. Pharmacol. Ther., 1994, 56, 615-25
12. Harte, G. J.; Gray, P. H.; Lee, T. C.; Steer, P. A.; Charles, B. G. Haemodynamic responses and population pharmacokinetics of mi-dazolam following administration to ventilated, preterm neonates. Paediatr. Child Health, 1997, 33, 335-8.
13. Lee, T. C.; Charles, B. G.; Harte, G. J.; Gray, P. H.; Steer, P. A.; Flenady, V. J. Population pharmacokinetic modeling in very premature infants receiving midazolam during mechanical ventilation: midazolam neonatal pharmacokinetics. Anesthesiology, 1999, 90, 451-7
14. De Wildt, S. N.; Kearns, G. L.; Hop, W. C.; Murry, D. J.; Abdel-Rahman, S. M.; van den Anker, J. N. Pharmacokinetics and metabolism of intravenous midazolam in preterm infants. Clin. Pharmacol. Ther., 2001, 70, 525-31
15. Mathews, H. M.; Carson, I. W.; Lyons, S. M.; Orr, I. A.; Collier, P. S.; Howard, P. J.; Dundee, J. W. A pharmacokinetic study of midazolam in paediatric patients undergoing cardiac surgery. Br. J. Anaesth., 1988, 61, 302-7
16. Payne, K.; Mattheyse, F. J.; Liebenberg, D.; Dawes, T. The phar-macokinetics of midazolam in paediatric patients. Eur. J. Clin. Pharmacol., 1989, 37, 267-72
17. Reed, M. D.; Rodarte, A.; Blumer, J. L.; Khoo, K. C.; Akbari, B.; Pou, S.; Kearns, G. L. Pediatric Pharmacology Research Unit Network. The single-dose pharmacokinetics of midazolam and its primary metabolite in pediatric patients after oral and intravenous administration. J. Clin. Pharmacol., 2001, 41, 1359-69
18. De Wildt, S. N.; de Hoog, M.; Vinks, A. A.; van der Giesen, E.; van den Anker, J. N. Population pharmacokinetics and metabolism of midazolam in pediatric intensive care patients. Crit. Care Med., 2003, 31, 1952-8
19. Peeters, M. Y.; Prins, S. A.; Knibbe, C. A.; Dejongh, J.; Mathôt, R. A.; Warris, C.; van Schaik, R. H.; Tibboel, D.; Danhof, M. Phar-macokinetics and pharmacodynamics of midazolam and metabolites in nonventilated infants after craniofacial surgery. Anesthesi-ology, 2006, 105, 1135-46
20. Nahara, M. C.; McMorrow, J.; Jones, P. R.; Anglin, D.; Rosenberg, R. Pharmacokinetics of midazolam in critically ill pediatric patients. Eur. J. Drug Metab. Pharmacokinet., 2000, 5, 219-21
21. Ahsman, M. J.; Hanekamp, M.; Wildschut, E. D.; Tibboel, D.; Mathot, R. Population pharmacokinetics of midazolam and its metabolites during venoarterial extracorporeal membrane oxygenation in neonates. Clin. Pharmacokinet., 2010, 49, 407-19
22. Mulla, H.; McCormack, P.; Lawson, G.; Firmin, R. K.; Upton, D. R. Pharmacokinetics of midazolam in neonates undergoing extra-corporeal membrane oxygenation. Anesthesiology, 2003, 99, 275-82
23. Muchohi, S. N.; Kokwaro, G. O.; Ogutu, B. R.; Edwards, G.; Ward, S. A.; Newton, C. R. Pharmacokinetics and clinical efficacy of midazolam in children with severe malaria and convulsions. Br. J. Clin. Pharmacol., 2008, 66, 529-38
24. Strolin Benedetti, M.; Whomsley, R.; Baltes, E. L. Differences in absorption, distribution, metabolism and excretion of xenobiotics between the paediatric and adult populations. Expert Opin. Drug Metab. Toxicol., 2005, 1, 447-71
25. Björkman, S. Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs. Br. J. Clin. Pharmacol., 2004, 59, 691-704
26. Anderson, B. J.; McKee, A. D.; Holford, N. H. Size, myths and the clinical pharmacokinetics of analgesia in paediatric patients. Clin. Pharmacokinet., 1997, 33, 313-27
27. Johnson, T. N.; Rostami-Hodjegan, A.; Goddard, J. M.; Tanner, M. S.; Tucker, G. T. Contribution of midazolam and its 1-hydroxy metabolite to preoperative sedation in children: a pharmacokinetic-pharmacodynamic analysis. Br. J. Anaesth., 2002, 87, 428-37
28. De Wildt, S. N.; Kearns, G. L.; Leeder, J. S.; van den Anker, J. N. Cytochrome P450 3A: ontogeny and drug disposition. Clin. Phar-macokinet., 1999, 37, 485-505
29. Hines, R. N. Ontogeny of human hepatic cytochromes P450. J. Biochem. Mol. Toxicol., 2007, 21, 169-75
30. Stevens, J. C. New perspectives on the impact of cytochrome P450 3A expression for pediatric pharmacology. Drug Discov. Today, 2006, 11, 440-5
31. Alcorn, J.; McNamara, P. J. Ontogeny of hepatic and renal systemic clearance pathways in infants. Part II. Clin. Pharmacokinet., 2002, 41, 1077-94
32. Zhu, B.; Bush, D.; Doss, G. A.; Vincent, S.; Franklin, R. B.; Xu, S. Characterization of 1'-hydroxymidazolam glucuronidation in human liver microsomes. Drug Metab. Disp., 2008, 36, 331-8
33. Klieber, S.; Hugla, S.; Ngo, R.; Arabeyre-Fabre, C.; Meunier, V.; Sadoun, F.; Fedeli, O.; Rival, M.; Bourrie, M.; Guillou, F.; Maurel, P.; Fabre, G. Contribution of the N-glucuronidation pathway to the overall in vitro metabolic clearance of midazolam in humans. Drug Metab. Dispos., 2008, 36, 851-62.
34. Hyland, R.; Osborne, T.; Payne, A.; Kempshall, S.; Logan, Y. R.; Ezzeddine, K.; Jones, B. In vitro and in vivo glucuronidation of midazolam in humans. Br. J. Clin. Pharmacol., 2009, 67, 445-54
35. De Wildt, S. N.; Kearn, G. L.; Leeder, J. S.; van den Anker, J. N. Glucuronidation in humans. Pharmacogenetic and developmental aspects. Clin. Pharmacokinet., 1999, 36, 439-52
36. Strassburg, C. P.; Strassburg, A.; Kneip, S.; Barut, A.; Tukey, R. H.; Rodeck, B.; Manns, M. P. Developmental aspects of human hepatic drug glucuronidation in young children and adults. Gut, 2002, 50, 259-65
37. Miyagi, S. J.; Collier, A. C. Pediatric development of glucuronida-tion: the ontogeny of hepatic UGT1A4. Drug Metab. Dispos., 2007, 35, 1587-92
38. De Wildt, S. N.; Kearns, G. L.; Murry, D. J.; Koren, G.; van den Anker, J. N. Ontogeny of midazolam glucuronidation in preterm infants. Eur. J. Clin. Phrmacol., 2010, 66, 165-70
39. Robillard JE. Glomerular Filtration. In: Gluckman PD, Heymann MA (eds) Pediatrics and perinatology, the scientific basis, 2nd ed. Arnold, London, 1996 pp. 939-941
40. Bauer, T. M.; Ritz, R.; Haberthür, C.; Ha, H. R.; Hunkeler, W.; Sleight, A. J.; Scollo-Lavizzari, G.; Haefeli, W. E. Prolonged sedation due to accumulation of conjugated metabolites of midazolam. Lancet, 1995, 346, 145-7
41. Driessen, J. J.; Vree, T. B.; Guelen, P. J. M. The effects of acute changes in renal function on the pharmacokinetics of midazolam during long-term infusion in ICU patients. Acta. Anaesth. Belg., 1991, 42, 149-155
42. Ma, W.; Saunders, P. A.; Somogyi, R.; Poulter, M. O.; Barker, J. L. Ontogeny of GABAA receptor subunit mRNAs in rat spinal cord and dorsal root ganglia. J. Comp. Neurol., 1993, 338, 337-59
43. Ben-Ari, Y. Excitatory actions of GABA during development: the nature of the nurture. Nat. Rev. Neurosci., 2002, 3, 728-39
44. Koch, S. C.; Fitzgerald, M.; Hathway, G. J. Midazolam potentiates nociceptive behavior, sensitizes cutaneous reflexes, and is devoid of sedative action in neonatal rats. Anesthesiology, 2008, 108, 122-9
45. Reichelt, R.; Hofmann, D.; Fodisch, H. J.; Mohler, H.; Knapp, M.; Hebebrand, J. Ontogeny of the benzodiazepine receptor in human brain: fluorographic, immunochemical, and reversible binding studies. J. Neurochem., 1991, 57, 1128-35
46. Chugani, D. C.; Muzik, O.; Juhasz, C.; Janisse, J. J.; Ager, J.; Chugani, H. T. Postnatal maturation of human GABAA receptors measured with positron emission tomography. Ann. Neurol., 2001, 49, 618-26
47. Malizia, A. L.; Gunn, R. N.; Wilson, S. J.; Waters, S. H.; Bloomfield, P. M.; Cunningham, V. J.; Nutt, D. J. Benzodiazepine site pharmacokinetic/ pharmacodynamic quantification in man: direct measurement of drug occupancy and effects on the human brain in vivo. Neuropharmacology, 1996, 35, 1483-91
48. Booker, P. D.; Beechey, A.; Lloyd-Thomas, A. R. Sedation of childrem requiring artificial ventilation using an infusion of mida-zolam. Br. J. Anaesth., 1986, 58, 1104-8
49. Lloyd-Thomas, A. R.; Booker, P. D. Infusion of midazolam in paediatric patienst after cardiac surgery. Br. J. Anaesth., 1986, 58, 110-15
50. Silvasi, D. L.; Rosen, D. A.; Rosen, K. R. Continuous intravenous midazolam infusion for sedation in the pediatric intensive care unit. Anesth. Analg., 1988, 67, 286-8
51. Hartwig, S.; Roth, B.; Theisohn, M. Clinical experience with con-tinous intravenous sedation using midazolam and fentanyl in the paediatric intensive care unit. Eur. J. Pediatr., 1991, 150, 784-8
52. Rosen, D. A.; Rosen, K. R. Midazolam for sedation in the paediat-ric intensive care unit. Intensive Care Med., 1991, 17, S15-9
53. Sheridan, R. l.; McEttricj, M.; Bacha, G.; Stoddard, F.; Tompins, R. G. Midazolam infusion in pediatric patients with burns who are undergoing mechanical ventilation. J. Burn. Care Rehabil., 1994, 15, 515-8
54. Playfor, S. D.; Thomas, D. A.; Choonara, I.; Jarvis, A. Quality of sedation during mechanical ventilation. Paediatr. Anaesth., 2000, 10, 195-9
55. de Wildt, S. N.; de Hoog, M.; Vinks, A. A.; Joosten, K. F.; van Dijk, M.; van den Anker, J. N. Pharmacodynamics of midazolam in pediatric intensive care patients. Ther. Drug Monit., 2005, 27, 98-102
56. Tobias, J. D.; Berkenbosch, J. W. Sedation during mechanical ventilation in infants and children: dexmedetomidine versus mida-zolam. South Med. J., 2004, 97, 451-5
57. Treluyer, J. M.; Zohart, S.; Rey, E.; Hubert, P.; Iserin, F.; Jugies, M.; Lenclen, R.; Chevret, S.; Pons, G. Minimum effective dose of midazolam for sedati0n of mechanically ventilated neonates. J. Clin. Pharmacy Ther., 2005, 30, 479-85
58. Hartman, M. E.; McCrory, D. C.; Schulman, S. R. Efficacy of sedation regimens to facilitate mechanical ventilation in the pediat-ric intensive care unit: a systematic review. Pediatr. Crit. Care Med., 2009, 10, 246-55
59. Trouiller, P.; Fangio, P.; Paugam-Burtz, C.; Appéré-de- Vecchi, C.; Merckx, P.; Louvet, N.; Pease, S.; Outin, H.; Mantz, J.; De Jonghe, B. Frequency and clinical impact of preserved bispectral index activity during deep sedation in mechanically ventilated ICU patients. Intensive Care Med., 2009, 35, 2096-104
60. Arbour, R.; Waterhouse, J.; Seckel, M. A.; Bucher, L. Correlation between the Sedation-Agitation Scale and the Bispectral Index in ventilated patients in the intensive care unit. Heart Lung, 2009, 38, 336-45
61. Björkman, S. Prediction of cytochrome P450-mediated hepatic drug clearance in neonates, infants and children. Clin. Pharma-cokinet., 2006, 42, 1-11
62. Johnson, T. N.; Rostami-Hodjegan, A.; Tucker, G. T. Prediction of the clearance of eleven drugs and associated variability in neo-nates, infants and children. Clin. Pharmacokinet., 2006, 45, 931-5663
63. Malviya, S.; Voepel-Lewis, T.; Tait, A. R.; Watcha, M. F.; Sadha-sivam, S.; Friesen, R. H. Effect of age and sedative agent on the accuracy of bispectral index in detecting depth of sedation in children. Pediatrics, 2007, 120, 461-70
64. Vet, N. J.; de Hoog, M.; Tibboel, D.; de Wildt, S. N. The effect of critical illness and inflammation on midazolam therapy in children. Pediatr. Crit. Care Med., 2010, 2010 Nov 4. [Epub ahead of print]